Ceftazidime dosage regimen in intensive care unit patients: From a population pharmacokinetic approach to clinical practice via Monte Carlo simulations

British Journal of Clinical Pharmacology

Volumn 73, Issue 4, 2012, Pages 588-596

  Georges, Bernard ^a,b   Conil, Jean Marie ^a,b   Ruiz, Stéphanie ^a,b   Seguin, Thierry ^a,b   Cougot, Pierre ^a   Fourcade, Olivier ^a,b   Houin, Georges ^c   Saivin, Sylvie ^b,c  

^a CHU RANGUEIL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c Institut Federatif de Biologie   (France)

Author keywords

Ceftazidime; Dosage regimen; Intensive care patients; Pharmacodynamics; Pharmacokinetics; Simulation

Indexed keywords

CEFTAZIDIME;

ANALYTICAL PARAMETERS; ARTICLE; CLINICAL PRACTICE; CONTINUOUS INFUSION; DIET THERAPY; DRUG DIFFUSION; EUROPEAN BREAK POINT; GLOMERULUS FILTRATION RATE; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MODIFICATION OF THE DIET IN RENAL DISEASE; MONTE CARLO METHOD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; STEADY STATE;

ANTI-BACTERIAL AGENTS; CEFTAZIDIME; COMPUTER SIMULATION; CRITICAL CARE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PNEUMONIA, BACTERIAL; PSEUDOMONAS INFECTIONS; RESPIRATION, ARTIFICIAL;

EID: 84858176753     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04117.x     Document Type: Article

References (50)

1. Sun HK, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program. Crit Care Med 2005; 33: 2222-7.
2. Vinks AA, Mouton JW, Touw DJ, Heijerman HG, Danhof M, Bakker W. Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy. Antimicrob Agents Chemother 1996; 40: 1091-7.
3. Bulitta JB, Landersdorfer CB, Huttner SJ, Drusano GL, Kinzig M, Holzgrabe U, Stephan U, Sorgel F. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2010; 54: 1275-82.
4. Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL, Jacobs F. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010; 14: R53.
5. Roberts JA, Roberts MS, Semark A, Udy AA, Kirkpatrick CM, Paterson DL, Roberts MJ, Kruger P, Lipman J. Antibiotic dosing in the 'at risk' critically ill patient: linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol 2011; 11: 3.
6. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F. Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010; 14: R126.
7. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 2003; 47: 548-53.
8. Georges B, Conil JM, Seguin T, Ruiz S, Minville V, Cougot P, Decun JF, Gonzalez H, Houin G, Fourcade O, Saivin S. Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation and reason for admission. Antimicrob Agents Chemother 2009; 53: 4483-9.
9. Joukhadar C, Frossard M, Mayer BX, Brunner M, Klein N, Siostrzonek P, Eichler HG, Muller M. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001; 29: 385-91.
10. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45: 755-73.
11. Georges B, Conil JM, Dubouix A, Archambaud M, Bonnet E, Saivin S, Lauwers-Cances V, Cristini C, Cougot P, Decun JF, Mathe O, Chabanon G, Marty N, Seguin T, Houin G. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units. Crit Care Med 2006; 34: 1636-41.
12. Girardi C, Tonnellier M, Goldstein I, Sartorius A, Wallet F, Rouby JJ. Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia. Intensive Care Med 2006; 32: 2042-8.
13. Frei CR, Burgess DS. Continuous infusion beta-lactams for intensive care unit pulmonary infections. Clin Microbiol Infect 2005; 11: 418-21.
14. Boselli E, Breilh D, Rimmele T, Poupelin JC, Saux MC, Chassard D, Allaouchiche B. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004; 30: 989-91.
15. Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, Jacobs F. Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011; 15: R137.
16. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31: 345-51.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
18. Aubert G, Carricajo A, Coudrot M, Guyomarc'h S, Auboyer C, Zeni F. Prospective determination of serum ceftazidime concentrations in intensive care units. Ther Drug Monit 2010; 32: 517-9.
19. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994; 38: 931-6.
20. Mouton JW, Punt N, Vinks AA. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 2005; 27: 762-72.
21. Bergogne-Berezin E, Pierre J, Berthelot G, Kafe H, Even P, Gibert C, Safran D, Stern M. [Bronchial diffusion of new anti-pseudomonal beta-lactams. Clinical significance]. Pathol Biol 1984; 32: 421-5.
22. Jallon P, Fankhauser L, Du Pasquier R, Coeytaux A, Picard F, Hefft S, Assal F. Severe but reversible encephalopathy associated with cefepime. Neurophysiol Clin 2000; 30: 383-6.
23. Andes D, Anon J, Jacobs MR, Craig WA. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med 2004; 24: 477-502.
24. DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy 2007; 27: 333-42.
25. Cavallo JD, Merens A. [Pseudomonas aeruginosa and beta-lactam antibiotics at the time of Europe]. Pathol Biol 2008; 56: 435-8.
26. Bressolle F, Gomeni R. Predictive performance of a semiparametric method to estimate population pharmacokinetic parameters using NONMEM. J Pharmacokinet Biopharm 1998; 26: 349-61.
27. Craig WA. Proof of concept: performance testing in models. Clin Microbiol Infect 2004; 10: (Suppl. 2): 12-7.
28. Tam VH, Louie A, Lomaestro BM, Drusano GL. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy 2003; 23: 291-5.
29. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998; 27: 10-22.
30. Lee SY, Kuti JL, Nicolau DP. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. J Infect 2007; 54: 463-8.
31. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50: 425-8.
32. Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54: 1111-6.
33. Nicolau DP, Onyeji CO, Zhong M, Tessier PR, Banevicius MA, Nightingale CH. Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations. Antimicrob Agents Chemother 2000; 44: 1291-5.
34. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. Tissue concentrations: do we ever learn? J Antimicrob Chemother 2008; 61: 235-7.
35. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008; 52: 24-36.
36. Kieft H, Hoepelman AI, Knupp CA, van Dijk A, Branger JM, Struyvenberg A, Verhoef J. Pharmacokinetics of cefepime in patients with the sepsis syndrome. J Antimicrob Chemother 1993; 32: (Suppl. B): 117-22.
37. Theuretzbacher U. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Curr Opin Pharmacol 2007; 7: 498-504.
38. Bergogne-Berezin E. Antibiotic tissue concentrations revisited in lungs. Crit Care Med 2003; 31: 2242-3.
39. Jackson GD, Berkovic SF. Ceftazidime encephalopathy: absence status and toxic hallucinations. J Neurol Neurosurg Psychiatry 1992; 55: 333-4.
40. Conil JM, Georges B, Lavit M, Seguin T, Tack I, Samii K, Chabanon G, Houin G, Saivin S. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance. Int J Clin Pharmacol Ther 2007; 45: 529-38.
41. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010; 35: 156-63.
42. Zubert S, Funk DJ, Kumar A. Antibiotics in sepsis and septic shock: like everything else in life, timing is everything. Crit Care Med 2010; 38: 1211-2.
43. Gomez CM, Cordingly JJ, Palazzo MG. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999; 43: 1798-802.
44. Zagli G, Tarantini F, Bonizzoli M, Di Filippo A, Peris A, De Gaudio AR, Geppetti P. Altered pharmacology in the intensive care unit patient. Fundam Clin Pharmacol 2008; 22: 493-501.
45. Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 1999; 43: 309-11.
46. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH, Banevicius MA, Fu Q. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001; 17: 497-504.
47. Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 2007; 30: 11-8.
48. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64: 142-50.
49. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49: 1-16.
50. Udy AA, Putt MT, Shanmugathasan S, Roberts JA, Lipman J. Augmented renal clearance in the Intensive Care Unit: an illustrative case series. Int J Antimicrob Agents 2010; 35: 606-8.